Dementia risk reduction doesn't require waiting for blood tests, experts say

The conversation around dementia has shifted. For years, the implicit message was clear: wait for the science to catch up. Wait for the blood test. Wait for the breakthrough. But a growing body of research is now saying something different—that the most powerful tool for reducing dementia risk is already in your hands, and it doesn't require a laboratory or a doctor's order.

This matters because the landscape of Alzheimer's diagnosis is changing rapidly. Multiple blood tests designed to detect early signs of Alzheimer's disease are moving through the market, each promising earlier detection and more precise prediction of when cognitive decline might begin. These tests measure biomarkers—proteins and other indicators in the bloodstream that suggest the disease process is underway, sometimes years before symptoms appear. The promise is real. The problem is more complicated.

The tests themselves are becoming available, but questions about cost, access, and what to actually do with the results remain unsettled. Not everyone can afford them. Not every doctor knows how to interpret them. And for many people, getting a positive result without a clear treatment pathway can feel more like a sentence than a tool. Meanwhile, the companies developing these tests are competing for market share, which means the pressure to adopt them—to make them standard, to integrate them into routine screening—is mounting.

But here's what the research is increasingly showing: you don't have to wait. The interventions that reduce dementia risk are not exotic. They are not expensive. They do not require a blood draw or a specialist's consultation. They require attention to the basics—the things that have always mattered for brain health. Regular physical activity. Cognitive engagement. Social connection. Sleep quality. Diet. Hearing correction. Blood pressure management. These are not new discoveries. What is new is the confidence with which researchers can now say that these steps, taken seriously and sustained over time, can meaningfully lower the risk of cognitive decline.

The timing of this message is significant. As Alzheimer's blood tests jockey for position in the diagnostic marketplace, with questions about which tests are most reliable and which will become standard of care, the research community is essentially saying: don't let the perfect be the enemy of the good. You have agency right now. You have evidence-based actions you can take today. The blood tests may eventually play a role in identifying who needs more aggressive intervention, but they should not be the gatekeeper to dementia prevention.

There is also a policy dimension emerging. Congress is being asked to consider legislation—the ASAP Act—that would help ensure equitable access to both preventive strategies and diagnostic tools. The concern is straightforward: if blood tests become the standard for identifying dementia risk, but access is limited by cost or geography, then the people who need help most may be the ones least likely to get it. And if the focus shifts entirely to testing and away from the proven interventions, then even those with access to the tests may not benefit.

What experts are saying, in effect, is this: the future of dementia prevention is not either-or. It is not blood tests or lifestyle change. It is both, deployed thoughtfully, with the understanding that the lifestyle interventions are available now and they work. The blood tests may help refine who needs what level of intervention, but they should not delay anyone from starting. The person reading this does not need to wait for a test result to begin walking more, sleeping better, or strengthening their social ties. The evidence is there. The opportunity is now.